Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.


Docetaxel-based therapy is established as the standard first-line chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC), based on results from two landmark Phase III studies. However, prognosis remains poor, with a median survival of less than 2 years. There is no standard of care for patients who progress during or after… (More)
DOI: 10.1111/j.1464-410X.2010.10036.x


3 Figures and Tables